Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22186847 | 0.96 | TGFBR1 (0.60) | TGFBR1TGFB1 | |
| SCHEMBL17645167 | 0.94 | TGFBR1 (0.57) | TGFBR1TGFB1 | |
| SCHEMBL17645445 | 0.92 | TGFBR1 (0.53) | TGFBR1TGFB1 | |
| SCHEMBL28397649 | 0.91 | TGFBR1 (0.54) | TGFBR1TGFB1 | |
| SCHEMBL28888969 | 0.90 | TGFBR1 (0.57) | TGFBR1TGFB1 | |
| SCHEMBL24263214 | 0.90 | TGFBR1 (0.52) | TGFBR1TGFB1 | |
| SCHEMBL17645399 | 0.90 | TGFBR1 (0.52) | TGFBR1TGFB1 | |
| SCHEMBL22186882 | 0.89 | TGFBR1 (0.51) | TGFBR1TGFB1 | |
| SCHEMBL28676561 | 0.87 | TGFBR1 (0.64) | TGFBR1TGFB1 | |
| SCHEMBL28400915 | 0.87 | TGFBR1 (0.67) | TGFBR1TGFB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357260-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS THEREFOR, AND METHODS OF USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357260-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS THEREFOR, AND METHODS OF USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| CN-111196804-B | TGF-beta R1 inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-11691981-B2 | Heterocyclic compounds, preparation methods therefor, and methods of uses thereof | InventisBio Co., Ltd. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-11691981-B2 | Heterocyclic compounds, preparation methods therefor, and methods of uses thereof | InventisBio Co., Ltd. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-20220054465-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3902796-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | Nexys Therapeutics, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| CN-113348167-A | (pyridin-2-yl) amine derivatives as TGF-beta R1(ALK5) inhibitors for the treatment of cancer | 奈可萨斯医药有限公司 | 2021-09-03 | — | — | CN | disclosed |
| US-20210017187-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS THEREFOR, AND METHODS OF USES THEREOF | InventisBio Co., Ltd. (CN) | 2021-01-21 | — | — | US | disclosed |
| WO-2020139636-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| EP-3204377-B1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2018-09-26 | — | — | EP | disclosed |
| EP-3204377-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | Eli Lilly and Company (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9617243-B2 | Aminopyridyloxypyrazole compounds | ELI LILLY AND COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617243-B2 | Aminopyridyloxypyrazole compounds | ELI LILLY AND COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617243-B2 | Aminopyridyloxypyrazole compounds | ELI LILLY AND COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| WO-2016057278-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057278-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357260-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS THEREFOR, AND METHODS OF USES THEREOF | TGFB1, TGFB2, TGFBR1 | TGFBR1 3/4885TGFB1 1/4885 |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | TGFBR1, TGFBR2, PDGFRB | TGFBR1 1/4885TGFB1 14/4885 |
| US-20210017187-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS THEREFOR, AND METHODS OF USES THEREOF | TGFB1, TGFB2, TGFBR1 | TGFBR1 3/4885TGFB1 1/4885 |
| US-20220054465-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | TGFBR1, TGFBR2, ACVR1 | TGFBR1 1/4885TGFB1 9/4885 |
| US-11691981-B2 | Heterocyclic compounds, preparation methods therefor, and methods of uses thereof | TGFB1, TGFB2, TGFBR1 | TGFBR1 3/4885TGFB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.